1
|
Lorini L, Gili R, Salvestrini V, Morelli I, Smussi D, Petrelli F, Bonomo P, Bossi P. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter? Oral Oncol 2024; 152:106768. [PMID: 38552469 DOI: 10.1016/j.oraloncology.2024.106768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 03/19/2024] [Accepted: 03/21/2024] [Indexed: 05/01/2024]
Abstract
De novo metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) constitutes 10% of recurrent/metastatic (RM) cases. Radiotherapy (RT) has a crucial role in the treatment of locally advanced HNSCC, however its application on RM diseases is still limited. The advent of immune checkpoint inhibitors (ICIs) improves the survival of RM HNSCC, however median overall survival is still limited. Integration of locoregional RT with ICIs in de novo metastatic HNSCC represents a promising treatment option. This perspective aims to explore the role of the combination of locoregional and systemic treatment in improving outcomes for synchronous de novo metastatic HNSCC patients and highlights the principal crucial point in decision making.
Collapse
Affiliation(s)
- L Lorini
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
| | - R Gili
- Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
| | - V Salvestrini
- Radiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy
| | - I Morelli
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
| | - D Smussi
- Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy
| | - F Petrelli
- Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy
| | - P Bonomo
- Radiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy
| | - P Bossi
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy
| |
Collapse
|
2
|
Salvestrini V, Becherini C, Desideri I, Simontacchi G, Loi M, Garlatti P, Bertini N, Bonaparte I, Mattioli C, Banini M, Morelli I, Meattini I, Bonomo P, Livi L. Long Term Clinical Outcomes of a Cohort of Lung-Only Oligometastatic HNSCC Patients Treated with SBRT. Int J Radiat Oncol Biol Phys 2023; 117:e601-e602. [PMID: 37785816 DOI: 10.1016/j.ijrobp.2023.06.1965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Oligometastatic disease in head and neck squamous cell carcinoma (HNSCC) is a rare setting. Local ablative therapies are the most adopted strategies although no evidence-based recommendations are currently published. The aim of our analysis was to update and report on long-term clinical outcomes of a cohort of HNSCC patients treated with stereotactic body radiotherapy (SBRT) for lung-only oligometastatic disease. MATERIALS/METHODS Eligible patients had 1 to 5 lung metastases. The oligometastatic pattern was classified as "de novo" (suitable for SBRT only) or "oligoprogressive" (after first line of systemic therapy). We evaluated time to progression (TTP) as the time from the last day of SBRT to disease progression or death from any cause. Predictive factors of better clinical outcome and survival analysis were performed by Cox regression and Kaplan Meier methods, respectively. RESULTS A cohort of 46 patients and 47 metastases were retrospectively evaluated. The median age was 67 years (range 37-86) and 87% of patients had a ECOG PS 0-1. HPV negative status (77%) and "de novo" oligometastatic pattern (78%) were reported by the majority of patients. After a median follow up of 28 months (range 2-88), median TTP and overall survival (OS) were 18 months (95% CI 4.8 - 31.2) and 62 months (95% CI 10,8 - 113.2), respectively. The median volume of planning target volume (PTV) was 20.4 cc (range 7.1-55.3). At univariate analysis, patients aged > 70 years reported a better TTP (p 0.013). No statistically significant correlation was observed in respect with gender (p 0.23), ECOG PS (p 0.34), oligometastatic pattern (p 0.13) and p16/HPV status (p 0.22). Out of 26 histologically proven metastases, we collected only 2 patients reporting concordance between p16/HPV positive status of primary tumor and lung metastases. Overall, 6 patients reported grade (G) 1-2 acute toxicity and no acute G3 adverse events were observed. CONCLUSION Our findings suggested that SBRT may improve clinical outcome prolonging time to progression and to systemic treatments in a properly selected cohort of HNSCC patients with lung-only oligometastatic disease. Distant metastases from HPV-related primary HNSCC should be tested for p16/HPV status given the clinical implications of HPV positivity for diagnosis and treatment.
Collapse
Affiliation(s)
- V Salvestrini
- Istituto Fiorentino di Cura e Assistenza (IFCA), CyberKnife Center, Florence, Italy
| | - C Becherini
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - I Desideri
- Department of Experimental Clinical and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - G Simontacchi
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - M Loi
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - P Garlatti
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - N Bertini
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - I Bonaparte
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - C Mattioli
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - M Banini
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - I Morelli
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - I Meattini
- Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy
| | - P Bonomo
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - L Livi
- Department of Experimental Clinical and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
| |
Collapse
|
3
|
Greto D, Loi M, Burchini L, Banini M, Bonaparte I, Angelini L, Carnevale MG, Mattioli C, Ganovelli M, Talamonti C, Arilli C, Zani M, Francolini G, Simontacchi G, Bonomo P, Campanacci DA, Livi L. Preoperative Radiotherapy of Soft Tissue Sarcoma with Simultaneous Integrated Boost: A Phase II Study. Int J Radiat Oncol Biol Phys 2023; 117:e320. [PMID: 37785145 DOI: 10.1016/j.ijrobp.2023.06.2359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Neoadjuvant radiotherapy to 50 Gy in 25 fractions is delivered in operable Soft Tissue Sarcoma (STS) patients to downstage the tumor and improve resectability, although at the expense of increased risk of wound dehiscence. Nonetheless, clear margin resection (R0) may not be achieved in tumors located in proximity of critical structures such as the neurovascular bundle (NVB), resulting in impaired local control. The aim of this study is to increase R0 rate through addition of an IMRT boost to the potential sites of suboptimal resection in STS patients receiving neoadjuvant RT. We report hereby the dosimetric results and safety results from the first 5 patients enrolled in this trial. MATERIALS/METHODS We designed a prospective monocentric interventional single-arm Phase II study enrolling locally advanced STS eligible for surgery. RT is administered in 25 daily fractions to include the MRI-based Gross Tumor Volume (GTV) and peritumoral tissue at risk of microscopic spread (CTV1) to a dose of 50 Gy (2Gy/fraction), with SIB (Simultaneous Integrated Boost) intensification to the tumor/dissection plane interface (CTV2) to a dose of 60 Gy (2.4 Gy/fraction). CTV2 delineation is approved by both a Radiation Oncologist and Surgeon. A margin of 0.5 cm is applied to both CTV to obtain PTV1 and PTV2. Concurrent anthracyclines-based chemotherapy (ChT) is allowed up to 3 cycles. Primary endpoint is R0 resection rate. Secondary endpoints include pathologic complete response rate, objective response rate, overall survival, local and distant progression-free survival, acute and chronic toxicity rate. To assess an increase in R0 rate from 81% to 97% assuming β = 80% e α = 0.05, 33 patients will be included. Dose constraints are summarized in Table1. At least 95% of the PTV1 and PTV2 should be covered by 95% the prescription dose up to a maximum allowed dose of 107%. RESULTS Five patients were included. Tumor was located in the limbs and in the trunk in respectively 4 and 1 patient. Mean age was 47 years (range: 19-67). Concurrent chemotherapy was performed in 2 patients. Mean GTV size was 228.6 cm3 (range: 59.8-314.5). Mean PTV coverage by the 95% of the dose prescription was 98% (95-100) and 97% (95-100) in PTV1 and PTV2, respectively. Mean PTV1 and PTV2 Dmax were 61.6 Gy (range: 59-63) and 64.1 Gy (range:63-66), in both cases below the 107% threshold. Mean Bone Dmax was 55 Gy (56.6-61.8 Gy). Dmax to the skin corridor exceeded 20 Gy in 1 patient (range 12.5-58.1). While the NVB was overlapping the PTV2 in all cases, Dmax was below 66 Gy. At the time of this report, no Grade ≥3 acute skin toxicity was observed. Two patients underwent surgery with a radiological partial response (RECIST) and pathological complete response. No major wound complication was reported. CONCLUSION Planning goals of the first 5 enrolled patients are achieved in most cases. Preliminary results show a benign safety profile and promising tumor response rate.
Collapse
Affiliation(s)
- D Greto
- Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Florence, Italy
| | - M Loi
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - L Burchini
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - M Banini
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - I Bonaparte
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - L Angelini
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - M G Carnevale
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - C Mattioli
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - M Ganovelli
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - C Talamonti
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - C Arilli
- Medical Physics, Careggi University Hospital, University of Florence, Florence, Italy
| | - M Zani
- Medical Physics, Careggi University Hospital, University of Florence, Florence, Italy
| | - G Francolini
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - G Simontacchi
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - P Bonomo
- Radiation Oncology, Careggi University Hospital, University of Florence, Florence, Italy
| | - D A Campanacci
- Department of Health Sciences, Orthopedic Oncology and Reconstructive Surgery Unit, Careggi University Hospital, University of Florence, Florence, Italy
| | - L Livi
- Department of Experimental Clinical and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy
| |
Collapse
|
4
|
Maggiore G, Fancello G, Gasparini A, Locatello LG, Orlando P, Chieca M, Caini S, Becherini C, Bonomo P, Gallo O. Temporal evolution of quality of life in patients endoscopically treated for sinonasal malignant tumors. Rhinology 2023:3058. [PMID: 36730816 DOI: 10.4193/rhin22.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The aim of our study is to assess which factors may affect the quality of life (QoL) and its fluctuation over time in adult patients who received endonasal endoscopic oncologic sinus surgery (EOSS) for sinonasal malignancies (SNM) in our center. METHODOLOGY We analyzed EOSS cases for primary SNM from January 2015 to June 2020. For each patient, we have recorded the age at treatment, gender, smoking habits, use of psychotropic drugs for mood disorders, stage, histotype, type of surgical resection, need for skull-base reconstruction, development of postoperative major complications, and the use of adjuvant intensity-modulated radiotherapy (IMRT). We evaluated the patient's performance status pre-treatment using the ECOG scale. Quality of life was measured using three questionnaires (SNOT-22; ASK-9; EORTC QLQ-C30 version 3). RESULTS Fifty-five patients were enrolled in our study, of whom thirty-two (58.18%) received adjuvant IMRT. Overall, a significant improvement in all QoL outcomes was observed at eighteen months, while, female sex, higher ECOG scores, advanced stage of disease, and adjuvant IMRT were associated with worse QoL. After 18 months the delta in QoL between women and men worsened (in SNOT-22 and EORTC QLQ-GLOBAL) while if only the most fragile patients according to ECOG are considered, this difference was reduced for both tools. CONCLUSION Our analysis revealed that IMRT is the element that has the greatest impact on patient's quality of life, in association with the female sex, ECOG >2, and advanced stage of the disease.
Collapse
Affiliation(s)
- G Maggiore
- Department of Otorhinolaryngology, Careggi University Hospital, Florence, Italy
| | - G Fancello
- Department of Otorhinolaryngology, Careggi University Hospital, Florence, Italy
| | - A Gasparini
- Department of Otorhinolaryngology, Careggi University Hospital, Florence, Italy
| | - L G Locatello
- Department of Otorhinolaryngology, Careggi University Hospital, Florence, Italy.,Department of Otorhinolaryngology, University Hospital Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
| | - P Orlando
- Department of Otorhinolaryngology, Careggi University Hospital, Florence, Italy
| | - M Chieca
- Institute for Cancer Research, Prevention, and Clinical Network (ISPRO), Florence, Italy
| | - S Caini
- Institute for Cancer Research, Prevention, and Clinical Network (ISPRO), Florence, Italy
| | - C Becherini
- Department of Radiation Oncology, Careggi University Hospital, Florence, Italy
| | - P Bonomo
- Department of Radiation Oncology, Careggi University Hospital, Florence, Italy
| | - O Gallo
- Department of Otorhinolaryngology, Careggi University Hospital, Florence, Italy.,Department of Clinical and Experimental Medicine, University of Florence, Italy
| |
Collapse
|
5
|
Meattini I, Becherini C, Visani L, Desideri I, Simontacchi G, Scotti V, Detti B, Francolini G, Loi M, Greto D, Bonomo P, Mangoni M, Barletta G, Livi L. OC-0935 Radiotherapy in patients receiving anthracyclines: phase 3 SAFE trial (NCT2236806) interim analysis. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02715-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Bonomo P. SP-0859 Slow intrafraction motion: MRI-based handling of non-periodic target deformations. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)04051-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Lucidi S, Bertini N, Loi M, Bonomo P, Francolini G, Greto D, Simontacchi G, Galardi A, Marrazzo L, Allegra A, Guerrieri B, Scoccimarro E, Mariotti M, Carnevale M, Stocchi G, Ciccone L, Peruzzi A, Lorenzetti V, Talamonti C, Pallotta S, Mangoni M, Livi L. PO-1324 Accelerated hypofractionation with SIB-IMRT in Anal Cancer : assessment of efficacy and toxicity. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03288-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Loi M, Bonucci I, Masi L, Doro R, Francolini G, Di Cataldo V, Bonomo P, Visani L, Tempobono M, Bellosi N, Pazzaglini S, Cassinelli M, Simontacchi G, Greto D, Desideri I, Lucidi S, Aquilano M, Livi L. PO-1469 CT-Guided Fiducial Placement for Robotic Stereotactic Body Radiotherapy: Efficacy and Safety. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03433-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Graziadei G, De Franceschi L, Sainati L, Venturelli D, Masera N, Bonomo P, Vassanelli A, Casale M, Lodi G, Voi V, Rigano P, Pinto VM, Quota A, Notarangelo LD, Russo G, Allò M, Rosso R, D'Ascola D, Facchini E, Macchi S, Arcioni F, Bonetti F, Rossi E, Sau A, Campisi S, Colarusso G, Giona F, Lisi R, Giordano P, Boscarol G, Filosa A, Marktel S, Maroni P, Murgia M, Origa R, Longo F, Bortolotti M, Colombatti R, Di Maggio R, Mariani R, Piperno A, Corti P, Fidone C, Palazzi G, Badalamenti L, Gianesin B, Piel FB, Forni GL. Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy. Front Med (Lausanne) 2022; 9:832154. [PMID: 35372393 PMCID: PMC8967327 DOI: 10.3389/fmed.2022.832154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Accepted: 02/14/2022] [Indexed: 11/30/2022] Open
Abstract
Sickle cell disease (SCD) is a worldwide distributed hereditary red cell disorder characterized by recurrent acute vaso-occlusive crises (VOCs and anemia). Gold standard treatments are hydroxycarbamide (HC) and/or different red blood cell (RBC) transfusion regimens to limit disease progression. Here, we report a retrospective study on 1,579 SCD patients (median age 23 years; 802 males/777 females), referring to 34 comprehensive Italian centers for hemoglobinopathies. Although we observed a similar proportion of Caucasian (47.9%) and African (48.7%) patients, Italian SCD patients clustered into two distinct overall groups: children of African descent and adults of Caucasian descent. We found a subset of SCD patients requiring more intensive therapy with a combination of HC plus chronic transfusion regimen, due to partial failure of HC treatment alone in preventing or reducing sickle cell-related acute manifestations. Notably, we observed a higher use of acute transfusion approaches for SCD patients of African descent when compared to Caucasian subjects. This might be related to (i) age of starting HC treatment; (ii) patients' low social status; (iii) patients' limited access to family practitioners; or (iv) discrimination. In our cohort, alloimmunization was documented in 135 patients (8.5%) and was more common in Caucasians (10.3%) than in Africans (6.6%). Alloimmunization was similar in male and female and more frequent in adults than in children. Our study reinforces the importance of donor-recipient exact matching for ABO, Rhesus, and Kell antigen systems for RBC compatibility as a winning strategy to avoid or limit alloimmunization events that negatively impact the clinical management of SCD-related severe complications.
Collapse
Affiliation(s)
- Giovanna Graziadei
- Rare Diseases Center, General Medicine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | - Laura Sainati
- Dipartimento della Salute della Donna e del Bambino Azienda Ospedaliera, Azienda Ospedaliera Universitaria, Padova, Italy
| | - Donatella Venturelli
- Servizio Immunotrasfusionale, Azienda Ospedaliero Universitaria Modena, Modena, Italy
| | - Nicoletta Masera
- Pediatric Clinic Hemato-Oncology Department, University of Milano-Bicocca, MBBM Foundation, San Gerardo Hospital, Monza, Italy
| | - Piero Bonomo
- Servizio Immunotrasfusionale, Azienda Ospedaliera Maria Paternò Arezzo, Ragusa, Italy
| | - Aurora Vassanelli
- UOC Medicina Trasfusionale, Azienda Ospedaliera Universitaria, Verona, Italy
| | - Maddalena Casale
- Department of Women, Child and General and Specialized Surgery, University “Luigi Vanvitelli”, Naples, Italy
| | - Gianluca Lodi
- Medicina Trasfusionale, Azienda Ospedaliera Universitaria Sant'Anna, Ferrara, Italy
| | - Vincenzo Voi
- Centro per le Emoglobinopatie – Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Ospedale San Luigi Gonzaga, Torino, Italy
| | - Paolo Rigano
- Campus of Haematology Franco e Piera Cutino, A.O.O.R. “Villa Sofia-Cervello” di Palermo, Palermo, Italy
| | - Valeria Maria Pinto
- Hematology, Thalassemia and Congenital Anemia Center, Ospedale Galliera, Genova, Italy
| | - Alessandra Quota
- Unità Operativa Semplice Dipartimentale Talassemia P.O. Vittorio Emanuele, Gela, Italy
| | - Lucia D. Notarangelo
- Italian Association of Pediatric Hematology Oncology (AIEOP) Coagulation Disorders Working Group, Brescia, Italy
| | - Giovanna Russo
- Pediatric Hematology/Oncology Unit, Università di Catania, Catania, Italy
| | - Massimo Allò
- Servizio Microcitemia, Presidio Ospedaliero SL 5, Crotone, Italy
| | - Rosamaria Rosso
- UOSD di Talassemia ed Emoglobinopatie, Azienda Ospedaliero-Universitaria Policlinico San Marco, Catania, Italy
| | - Domenico D'Ascola
- Centro Microcitemie, Azienda Ospedaliera “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy
| | - Elena Facchini
- SSD Oncoematologia Pediatrica - Policlinico di S.Orsola, Bologna, Italy
| | - Silvia Macchi
- Servizio Trasfusionale, Ospedale Santa Maria delle Croci, Ravenna, Italy
| | | | | | - Enza Rossi
- Unità Operativa Ematologia, Centro di Microcitemia, Azienda Ospedaliera di Cosenza, Presidio Ospedaliero “Annunziata” Cosenza, Cosenza, Italy
| | | | - Saveria Campisi
- Department of Talassemia, Siracusa Hospital, Siracusa, Italy
| | | | - Fiorina Giona
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - Roberto Lisi
- Unità Operativa Dipartimentale Talassemia, Presidio Garibaldi-Centro ARNAS Garibaldi, Catania, Italy
| | - Paola Giordano
- UOC Pediatria Universitaria, Università di Bari, Bari, Italy
| | | | - Aldo Filosa
- UOSD Malattie rare del globulo rosso, AORN A. Cardarelli, Naples, Italy
| | - Sarah Marktel
- Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Paola Maroni
- Servizio di Immunoematologia e Medicina Trasfusionale, ASST Sette Laghi, Varese, Italy
| | - Mauro Murgia
- Centro Provinciale per le Microcitemia, Ospedale San Martino di Oristano, Oristano, Italy
| | - Raffaella Origa
- Ospedale Pediatrico Microcitemico, Università di Cagliari, Cagliari, Italy
| | - Filomena Longo
- Hematology, Thalassemia and Congenital Anemia Center, Ospedale Galliera, Genova, Italy
| | - Marta Bortolotti
- Department of Oncology and Oncohematology, University of Milan, Milan, Italy
| | - Raffaella Colombatti
- Dipartimento della Salute della Donna e del Bambino Azienda Ospedaliera, Azienda Ospedaliera Universitaria, Padova, Italy
| | - Rosario Di Maggio
- Unità Operativa Semplice Dipartimentale Talassemia P.O. Vittorio Emanuele, Gela, Italy
| | - Raffaella Mariani
- Rare Disease Centre - Hereditary anemias - ASST-Monza, S. Gerardo Hospital - University of Milano-Bicocca, Monza, Italy
| | - Alberto Piperno
- Rare Disease Centre - Hereditary anemias - ASST-Monza, S. Gerardo Hospital - University of Milano-Bicocca, Monza, Italy
| | - Paola Corti
- Pediatric Clinic Hemato-Oncology Department, University of Milano-Bicocca, MBBM Foundation, San Gerardo Hospital, Monza, Italy
| | - Carmelo Fidone
- Servizio Immunotrasfusionale, Azienda Ospedaliera Maria Paternò Arezzo, Ragusa, Italy
| | - Giovanni Palazzi
- Servizio Immunotrasfusionale, Azienda Ospedaliero Universitaria Modena, Modena, Italy
| | - Luca Badalamenti
- Biomedicina, Neuroscienze e Diagnostica avanzata, University of Palermo, Palermo, Italy
| | | | - Frédéric B. Piel
- Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
| | - Gian Luca Forni
- Italian Association of Pediatric Hematology Oncology (AIEOP) Coagulation Disorders Working Group, Brescia, Italy
- *Correspondence: Gian Luca Forni
| |
Collapse
|
10
|
Becherini C, Banini M, Desideri I, Salvestrini V, Mariotti M, Caprara L, Scotti V, Agresti B, Garlatti P, Livi L, Bonomo P. Nivolumab in elderly patients with recurrent/metastatic head and neck squamous cell carcinoma: efficacy and safety data from a monocentric experience. J Geriatr Oncol 2021. [DOI: 10.1016/s1879-4068(21)00352-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Desideri I, Francolini G, Ciccone LP, Stocchi G, Salvestrini V, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L. Correction to: Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility. Support Care Cancer 2021; 30:1891-1892. [PMID: 34750667 PMCID: PMC8575545 DOI: 10.1007/s00520-021-06665-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Isacco Desideri
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy.
| | - G Francolini
- Radiation Oncology Unit, University of Florence, Florence, Italy.,CyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, Florence, Italy.,Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - L P Ciccone
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - G Stocchi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - V Salvestrini
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - M Aquilano
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - D Greto
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - P Bonomo
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - I Meattini
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy.,Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - V Scotti
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - S Scoccianti
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - G Simontacchi
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - L Livi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| |
Collapse
|
12
|
Francolini G, Loi M, Di Cataldo V, Detti B, Stocchi G, Allegra A, Bellini C, Aquilano M, Ciccone L, Mariotti M, Salvestrini V, Scoccimarro E, Valzano M, Simontacchi G, Bonomo P, Lucidi S, Desideri I, Meattini I, Livi L. PO-1316 Stereotactic radiotherapy in recurrent prostate cancer after postoperative or definitive irradiation. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07767-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
13
|
Bertini F, Arcelli A, Buwenge M, Macchia G, Guido A, Tolento G, Deodato F, Cilla S, Scotti V, Rosetto M, Djan I, Parisi S, Mattiucci G, Cellini F, Fiore M, Bonomo P, Belgioia L, Niespolo R, Gabriele P, Di Marco M, Simoni N, Mazzarotto R, Morganti A, Cammelli S. PD-0918 Stereobody radiotherapy vs chemoradiation in elderly with locally advanced pancreatic cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07197-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Ciccone L, Zani M, Scoccimarro E, Aquilano M, Banini M, Caprara L, Mariotti M, Salvestrini V, Becherini C, Desideri I, Marrazzo L, Pallotta S, Livi L, Bonomo P. PO-0997 Lack of CTV_P2 is not associated with a detrimental outcome in oropharyngeal cancer: a cohort study. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07448-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Loi M, Doro R, Lucidi S, Bonomo P, Simontacchi G, Greto D, Allegra A, Di Cataldo V, Francolini G, Bonucci I, Livi L, Masi L. PO-1226 Inhomogeneous dose escalation in pancreatic SBRT:feasibility and impact of anatomical configuration. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07677-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Arcelli A, Tarantino G, Buwenge M, Macchia G, Bertini F, Guido A, Deodato F, Cilla S, Scotti V, Rosetto M, Djan I, Parisi S, Mattiucci G, Cellini F, Fiore M, Bonomo P, Belgioia L, Niespolo R, Gabriele P, Di Marco M, Simoni N, Mazzarotto R, Morganti A. PH-0500 Outcome analysis in locally advanced pancreatic cancer: a predictive model (PAULA-1). Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07351-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Desideri I, Francolini G, Ciccone LP, Stocchi G, Salvestrini V, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L. Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility. Support Care Cancer 2021; 29:2931-2937. [PMID: 33006676 PMCID: PMC7531068 DOI: 10.1007/s00520-020-05793-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 09/18/2020] [Indexed: 01/09/2023]
Abstract
PURPOSE In the last months, Italy faced a COVID-19 emergency and implemented preventive measures in order to protect patients and healthcare providers from a disease outbreak. The pandemic control strategies impacted patient experience directly. Questionnaires evaluating patients reported measures (PREMs) may assess critical issues and represent a helpful tool to measure the patient perception of healthcare service. Our aim was to prospectively assess patient satisfaction about doctor-patient interaction in a high-volume radiation therapy and oncology center during the COVID-19 pandemic. METHODS Cancer patients receiving either systemic and/or radiation treatment underwent a survey. Two validated questionnaires (EORTC QLQ-C30, FACIT-TS-G version 1) and 14 specific questions evaluating patients' perception of COVID-19 measures were administered. RESULTS One hundred twenty-five patients admitted to our department from 1-30 April 2020 completed the questionnaires. The majority (66.4%) of patients were women and the most common disease was breast cancer (40%). The average Global Health Status (GHS) of EORTC QLQ-C30 was 61.67. Emotional functioning, social, and cognitive domains obtained scores of 75.48, 80.13, and 84.67, respectively. FACIT-TS-G results revealed 120 patients rated the treatments effective and 108 patients thought the side effects were the same as expected or better. Most (89.6%) rated their treatment good, very good, or excellent. Concerning COVID-19-related questions, patients reported overall very good level of information. CONCLUSIONS Despite the introduction of strict COVID-19 control measures, there was a high level of cancer outpatient satisfaction. The satisfaction levels may influence compliance, continuity of treatments, and patient-doctor communication, impacting the quality of clinical care in the next phases of the pandemic.
Collapse
Affiliation(s)
- Isacco Desideri
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy.
| | - G Francolini
- Radiation Oncology Unit, University of Florence, Florence, Italy
- CyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, Florence, Italy
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - L P Ciccone
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - G Stocchi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - V Salvestrini
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - M Aquilano
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - D Greto
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - P Bonomo
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - I Meattini
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - V Scotti
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - S Scoccianti
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - G Simontacchi
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - L Livi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| |
Collapse
|
18
|
Desideri I, Becherini C, Belgioia L, Merlotti A, Ciccone LP, Franzese C, Loi M, De Felice F, Mazzola R, Caini S, Livi L, Bonomo P. Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: A systematic review. Oral Oncol 2021; 119:105355. [PMID: 34044315 DOI: 10.1016/j.oraloncology.2021.105355] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 04/26/2021] [Accepted: 05/16/2021] [Indexed: 11/30/2022]
Abstract
Locally advanced Head and neck squamous cell carcinoma (SCCHN) represents a common oncologic pathology in older adults (OA). While radiotherapy represents a cornerstone in this context, it is unclear what is the optimal radiation regimen for SCCHN in the palliative setting, especially for OA. This article addresses issues related to palliative radiotherapy (PRT) in this setting with a focus on treatment modalities and toxicity. We also explore the use of quality of life and geriatric assessment in this setting. Medline, Scopus and Embase databases were queried for articles in this setting. We included studies published from January 1, 2000 through June 1, 2020, that were independently evaluated by two authors. Analyzed endpoints were progression free survival (PFS), overall survival (OS) and PRT toxicities. The meta-analysis was performed using Stata v.14. A total of 33 studies were included in this meta-analysis. The pooled median OS is 7.7 months, 2-years OS was worse for higher radiation dose (p = 0.02). The pooled median PFS was 5.4 months, PFS was influenced by EQD2 (p = 0.01), with patients receiving an EQD2 < 40 Gy that presented a poorer outcome. Regarding acute toxicities, most common pooled G3 toxicities were mucositis (7%) and dysphagia (15%). Among late toxicity, most common G3 toxicity was dysphagia in 7% of patients. Radiotherapy should be the most effective palliative treatment in symptomatic SCCHN OA. A tailored approach, guided by geriatric tools, would be indicated to choose the right therapy.
Collapse
Affiliation(s)
- I Desideri
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134 Florence, Italy.
| | - C Becherini
- Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy
| | - L Belgioia
- Department of Radiotherapy, Policlinico San Martino, University of Genoa, Genoa, Italy
| | - A Merlotti
- Department of Radiation Oncology, S. Croce and Carle Teaching Hospital, Cuneo, Italy
| | - L P Ciccone
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134 Florence, Italy
| | - C Franzese
- Humanitas Clinical and Research Center-IRCCS, Radiotherapy and Radiosurgery Dept., via Manzoni 56, 20089 Rozzano, MI, Italy; Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele-Milan, Italy
| | - M Loi
- Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy
| | - F De Felice
- Department of Radiological Science, Oncology and Human Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy
| | - R Mazzola
- Radiation Oncology Department, IRCCS, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy
| | - S Caini
- Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
| | - L Livi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134 Florence, Italy; Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy
| | - P Bonomo
- Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy
| |
Collapse
|
19
|
|
20
|
Mangoni M, Salvatore G, Greto D, Sottili M, Talamonti C, Lorenzetti V, Aquilano M, Peruzzi A, Salvestrini V, Visani L, Bonomo P, Scorianz M, Muratori F, Scoccianti G, Campanacci D, Livi L. PD-0067: An ex vivo assay to detect radiosensitization by PARP-inhibitors in soft tissue sarcomas. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00093-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
21
|
Vernaleone M, Bonomo P, Meduri B, Caramia G, Aluisio G, Visani L, Desideri I, Becherini C, D'Angelo E, Livi L, Lohr F. PO-1107: Impact of fractionation on the treatment of squamous cell anal cancer: a dual-institution experience. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01124-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
22
|
Bonomo P, Merlotti A, Morbelli S, Berti V, Saieva C, Bergesio F, Bacigalupo A, Belgioia L, Franzese C, Lopci E, Casolo A, D'Angelo E, Alterio D, Travaini L, Berretta L, Pirro V, Ursino S, Volterrani D, Roncali M, Vigo F, Desideri I, Russi E, Livi L, Bianchi A. PH-0040: A 6-point scale approach to 18F-FDG PET-CT for response assessment in HNSCC: a multicenter study. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00066-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Desideri I, Lucidi S, Garlatti P, Lorenzetti V, Ciabatti C, Terziani F, Scotti V, Bonomo P, Francolini G, Meattini I, Livi L. Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement for Aromatase Inhibitors-related Arthralgia Management (AIA): A prospective phase II trial (NCT04161833). Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30667-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Mannelli G, Santoro R, Bonomo P, Desideri I, Spinelli G. Will a tumor pandemic come after the COVID-19 pandemic? Head and Neck cancer perspective. Eur Rev Med Pharmacol Sci 2020; 24:8573-8575. [PMID: 32894562 DOI: 10.26355/eurrev_202008_22653] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The COVID-19 pandemic demands a reassessment of head and neck oncology treatment paradigms by posing several challenges for oncology services, with unprecedented pressure on the regional health care system. Since February 2020 this has severely disrupted health-care services, leading to accumulating clinic caseload and substantial delays for operations. The head and neck cancer services have been faced with the difficult task of managing the balance between infection risk to health-care providers and the risk of disease progression from prolonged waiting times. Herein, we share our experience in Firenze (Italy) and propose our action plan on the management of head and neck cancer services via multi-institution collaboration.
Collapse
Affiliation(s)
- G Mannelli
- Department of Experimental and Clinical Medicine, Head and Neck Oncology and Robotic Surgery, University of Florence, Florence, Italy.
| | | | | | | | | |
Collapse
|
25
|
Bonomo P, Desideri I, Mangoni M, Loi M, Saieva C, Marrazzo L, Talamonti C, Salvatore G, Sottili M, Teriaca M, Stocchi G, Cerbai C, Salvestrini V, Ganovelli M, Massi D, Gallo O, Santoro R, Spinelli G, Pallotta S, Livi L. 978TiP Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase I/II trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
26
|
Marrazzo L, Arilli C, Calusi S, Casati M, Talamonti C, Bonomo P, Livi L, Pallotta S. PO-0926 A novel approach to automatic planning: robust templates for lung VMAT SBRT. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31346-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Arcelli A, Bertini F, Morganti A, Guido A, Deodato F, Cilla S, Torre FD, Scotti V, Rosetto M, Djan I, Parisi S, Mattiucci G, Fiore M, Bonomo P, Bacigalupo A, Niespolo R, Gabriele P, Simoni N, Mazzarotto R, Macchia G. EP-1424 SBRT vs chemoradiation: a case-control study (PAULA-2). Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31844-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Bonomo P, Talamonti C, Marrazzo L, Desideri I, Pezzulla D, Dominici L, Rampini A, Bertocci S, De Majo R, Gasperi C, Curion A, Lastrucci L, Pallotta S, Livi L, Caini S. EP-1200 Is skin dose distribution a predictive factor for the development of severe radiation dermatitis? Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31620-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
Arcelli A, Macchia G, Guido A, Torre FD, Cilla S, Scotti V, Rosetto M, Djan I, Parisi S, Mattiucci G, Fiore M, Bonomo P, Bacigalupo A, Niespolo R, Gabriele P, Francesco D, Simoni N, Mazzarotto R, Morganti A. EP-1423 SBRT in locally advanced pancreatic cancer: a real-life study (PAULA-1). Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31843-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Bonomo P, Desideri I, Becherini C, Visani L, Salvestrini V, Mariotti M, Garlatti P, Dominici L, Livi L. PO-0731 Transition from anatomical to geometric expansion modality for high-risk CTV in oropharyngeal cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31151-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Bonomo P, Desideri I, Becherini C, Loi M, Orlandi E, Iacovelli N, Salvestrini V, Mariotti M, Visani L, Livi L. PO-09 Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic HNSCC. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30264-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Bonomo P, Desideri I, Loi M, Ciccone L, Russo ML, Becherini C, Visani L, Salvestrini V, Mariotti M, Pimpinelli N, Livi L. PO-148 Management of bio-radiation dermatitis in HNSCC: emphasizing the role of calcium alginate dressings. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30314-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
33
|
Le Tourneau C, Ghiani M, Cau M, Depenni R, Ronzino G, Bonomo P, Montesarchio V, Leo L, Schulten J, Messinger D, Sbrana A, Ghi M. Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
34
|
Franzese C, Tomatis S, Bossi P, Franco P, Bonomo P, Beltramo G, Bossi Zanetti I, Cante D, Argenone A, Musio D, Furlan C, Scorsetti M, Fallai C, Orlandi E. EP-1175: Role of Radiotherapy in the management of metastases from salivary gland carcinoma. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31485-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
35
|
Meattini I, Bernini M, Casella D, Maragna V, Sordi S, Desideri I, Gaggelli I, Dominici L, Fausto A, Delli Paoli C, Olmetto E, Francolini G, Loi M, Scotti V, Greto D, Bonomo P, Simontacchi G, Nori J, Bianchi S, Livi L. EP-1299: Postmastectomy radiation therapy after subcutaneous direct-to-implant breast reconstruction. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31609-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
36
|
Vernaleone M, Bonomo P, Di Cataldo V, Masi L, Desideri I, Greto D, Francolini G, Visani L, Olmetto E, Terziani F, Livi L. EP-1448: Robotic SBRT on liver lesions in oligometastatic CRC patients: a single center experience. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31757-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Arilli C, Wandael Y, Casati M, Marrazzo L, Galeotti C, Meattini I, Bonomo P, Simontacchi G, Pallotta S, Talamonti C. EP-1787: Use of two in vivo monitoring devices in the breast irradiation: an anthropomorphic phantom study. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32096-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
38
|
Greto D, Pezzulla D, Loi M, Terziani F, Caramia G, Lo Russo M, Teriaca A, Desideri I, Scoccianti S, Bonomo P, Meattini I, Simontacchi G, Livi L. EP-1186: Dosimetric comparison of planning modalities for GammaKnife radiosurgery of brain metastases. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31496-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
Heijmen B, Bonomo P, Goldner G, Henry A, Lohr F, Simontacchi G, Voet P, Fransen D, Penninkhof J, Milder M, Akhiat A, Casati M, Georg D, Lilley J, Marrazzo L, Pallotta S, Pellegrini R, Seppenwoolde Y, Steil V, Stieler F, Wilson S, Breedveld S. OC-0299: Inconsistencies in clinicians‘ final treatment plan evaluations – a need for automation support. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30609-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
40
|
Mahieu R, Colletti G, Bonomo P, Parrinello G, Iavarone A, Dolivet G, Livi L, Deganello A. Head and neck reconstruction with pedicled flaps in the free flap era. Acta Otorhinolaryngol Ital 2018; 36:459-468. [PMID: 28177328 PMCID: PMC5317124 DOI: 10.14639/0392-100x-1153] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 06/19/2016] [Indexed: 01/30/2023]
Abstract
Nowadays, the transposition of microvascular free flaps is the most popular method for management of head and neck defects. However, not all patients are suitable candidates for free flap reconstruction. In addition, not every defect requires a free flap transfer to achieve good functional results. The aim of this study was to assess whether pedicled flap reconstruction of head and neck defects is inferior to microvascular free flap reconstruction in terms of complications, functionality and prognosis. The records of consecutive patients who underwent free flap or pedicled flap reconstruction after head and neck cancer ablation from 2006 to 2015, from a single surgeon, in the AOUC Hospital, Florence Italy were analysed. A total of 93 patients, the majority with oral cancer (n = 59), were included, of which 64 were pedicled flap reconstructions (69%). The results showed no significant differences in terms of functional outcome, flap necrosis and complications in each type of reconstruction. Multivariate regression analysis of flap necrosis and functional impairments showed no associated factors. Multivariate regression analysis of complicated flap healing showed that only comorbidities remained an explaining factor (p = 0.019). Survival analysis and proportional hazard regression analysis regarding cancer relapse or distant metastasis, showed no significant differences in prognosis of patients concerning both types of reconstruction. In this retrospective, non-randomised study cohort, pedicled flaps were not significantly inferior to free flaps for reconstruction of head and neck defects, considering functionality, complications and prognosis.
Collapse
Affiliation(s)
- R Mahieu
- Department of Surgery and Translational Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy.,University of Groningen, University Medical Center Groningen, the Netherlands
| | - G Colletti
- Department of Maxillo-facial Surgery, University of Milan, Milan, Italy
| | - P Bonomo
- Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
| | - G Parrinello
- Department of Surgery and Translational Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
| | - A Iavarone
- Department of Surgery and Translational Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
| | - G Dolivet
- Department of Oncologic Surgery l'institut de Cancérologie de Lorraine, Nancy, France
| | - L Livi
- Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
| | - A Deganello
- Department of Surgery and Translational Medicine, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy
| |
Collapse
|
41
|
Loi M, Di Cataldo V, Simontacchi G, Detti B, Bonomo P, Masi L, Desideri I, Greto D, Francolini G, Carfora V, Pezzulla D, Perna M, Carta G, Livi L. Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer. Clin Oncol (R Coll Radiol) 2018; 30:93-100. [DOI: 10.1016/j.clon.2017.11.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 10/28/2017] [Accepted: 11/06/2017] [Indexed: 12/31/2022]
|
42
|
Vannini A, Meattini I, Grassi R, Carta G, Perna M, Becherini C, Garlatti P, Scotti V, Desideri I, Bonomo P, Livi L. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a routine oncology practice analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Zwirner K, Bonomo P, Lamprecht U, Zips D, Gani C. External validation of a rectal cancer outcome prediction model with a cohort of patients treated with preoperative radiochemotherapy and deep regional hyperthermia. Int J Hyperthermia 2017; 34:455-460. [DOI: 10.1080/02656736.2017.1338364] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Affiliation(s)
- K. Zwirner
- Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany
| | - P. Bonomo
- Radiotherapy Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy
| | - U. Lamprecht
- Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany
| | - D. Zips
- Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany
- Gastrointestinal Cancer Center, Comprehensive Cancer Center Tübingen-Stuttgart, Tübingen, Germany
- German Cancer Consortium (DKTK), partner site Tübingen; and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - C. Gani
- Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany
- Gastrointestinal Cancer Center, Comprehensive Cancer Center Tübingen-Stuttgart, Tübingen, Germany
- German Cancer Consortium (DKTK), partner site Tübingen; and German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
44
|
Mangoni M, Sottili M, Gualtieri T, Javarone A, Loi M, Meattini I, Bonomo P, Desideri I, Deganello A, Livi L. PO-0964: Biomarkers in wound drainage fluids affect response to radiations of head and neck cancer cells. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31400-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
45
|
Scoccianti S, Greto D, Calusi S, Poggesi L, Arilli C, Casati M, Compagnucci A, Becherini C, Carta G, Desideri I, Baki M, Visani L, Simontacchi G, Bonomo P, Bordi L, Bono P, Pallotta S, Livi L. EP-1127: Dose to hippocampus in brain metastases radiosurgery: need for an hippocampal sparing approach. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31563-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Loi M, Simontacchi G, Detti B, Di Cataldo V, Bonomo P, Masi L, Doro R, Bonucci I, Cipressi S, Desideri I, Greto D, Becherini C, Delli Paoli C, Grassi R, Lo Russo M, Meattini I, Scoccianti S, Mangoni M, Livi L. EP-1352: Single-fraction stereotactic body radiotherapy for nodal oligorecurrent prostate cancer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31787-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
47
|
Macchia G, Arcelli A, Morganti A, Bertini F, Guido A, Fuccio L, Dalla Torre F, Cilla S, Scotti V, Rosetto M, Djan I, Parisi S, Mattiucci G, Valentini V, Fiore M, Bonomo P, Bacigalupo A, Niespolo R, Gabriele P, Deodato F. PO-0680: SBRT for locally advanced pancreatic cancer (LAPC): a retrospective multi-institutional experience. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31117-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
Arcelli A, Bertini F, Morganti A, Guido A, Fuccio L, Deodato F, Cilla S, Dalla Torre F, Scotti V, Rosetto E, Djan I, Parisi S, Mattiucci G, Valentini V, Fiore M, Bonomo P, Bacigalupo A, Niespolo R, Gabriele P, Macchia G. PO-0681: SBRT VS standard chemoradiation in locally advanced pancreatic cancer (LAPC): a case-control study. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31118-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Di Cataldo V, Simontacchi G, Detti B, Loi M, Bonomo P, Masi L, Doro R, Bonucci I, Cipressi S, Greto D, Mangoni M, Desideri I, Meattini I, Scoccianti S, Olmetto E, Muntoni C, Carta G, Livi L. EP-1350: Stereotactic re-irradiation for prostate cancer recurrence after upfront surgery and radiotherapy. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31785-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Desideri I, Muntoni C, Ciabatti C, Lo Russo M, Bonomo P, Loi M, Greto D, Meattini I, Livi L. EP-1087: Real-world Cetuximab toxicity in curative and recurrent/metastatic setting in HNSCC patients. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31523-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|